Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial assessing safety and effectiveness of roluperidone for the treatment of negative symptoms in patients with Schizophrenia

Next Previous
Trial Profile

A clinical trial assessing safety and effectiveness of roluperidone for the treatment of negative symptoms in patients with Schizophrenia

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roluperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 04 Mar 2024 New trial record
  • 27 Feb 2024 According to a Minerva Neurosciences media release, In the CRL, the FDA cited some deficiency, to address these deficiencies, the FDA stated that Minerva must submit at least one additional positive, adequate, and well-controlled study to support the safety and effectiveness of roluperidone for the treatment of negative symptoms

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top